TermGallery
Inglês
Inglês
Espanhol
Catalão
Português
Russo
PT
English
Español
Català
Português
Русский
1
Background: Robust and precise molecular prognostic predictors for
luminal
breast
cancer are required.
2
This study illustrates the value of extended follow-up in trials of
luminal
breast
cancer.
3
Conclusions: We identified several key methylation sites and an mRNA signature for predicting
luminal
breast
cancer prognosis.
4
Furthermore, PDEF is essential for
luminal
breast
cancer cell survival and is required in models of endocrine resistance.
5
Methods: We compared methylation levels of normal and
luminal
breast
cancer samples from The Cancer Genome Atlas dataset.
6
Antiestrogen or estrogen receptor (ER)-targeted therapies to block ER action remain the primary treatment of
luminal
breast
cancers.
7
Here we describe patient-derived ER+
luminal
breast
tumor models for the study of intratumoral hormone and receptor action.
8
The transcription factor GATA3 is a key regulator of mammary gland development and a definitive marker of
luminal
breast
cancer.
9
This study aimed to identify key methylation sites in
luminal
breast
cancer, as well as precise molecular tools for predicting prognosis.
10
The signature exhibited effective and precise prediction of prognosis and may serve as a prognostic and diagnostic marker for
luminal
breast
cancer.
11
Purpose:
Luminal
breast
cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis.
luminal
breast
luminal